New treatment options and strengthened surveillance are helping to advance the global response to gonorrhoea and antimicrobial resistance.
Join WHO for a global webinar presenting new interim recommendations on two oral medicines for gonorrhoea: zoliflodacin and gepotidacin, and the launch of the 2026 WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) Report, featuring 2025 findings from 10 countries across 5 WHO regions.
Bringing together WHO experts, researchers and country representatives, the webinar will explore the latest evidence on gonococcal antimicrobial resistance, the responsible introduction of new treatments, and country experiences in strengthening surveillance.
The discussion will highlight how expanding treatment options, preserving antibiotic effectiveness and investment in research, surveillance and quality STI services can strengthen gonorrhoea prevention and care worldwide.
Date and time
Wednesday, 25 November 2026 | 11:00–12:30 CET
Objectives
- Present WHO interim recommendations on additional oral treatment options for gonorrhoea
- Launch and disseminate the key findings of the 2026 EGASP Report and their implications.
- Share country experiences and lessons learned in strengthening gonococcal antimicrobial resistance surveillance through EGASP.